Genetic Technologies Ltd
Genetic Technologies Limited is an Australia-based diversified molecular diagnostics company.
The business
Genetic Technologies Limited is an Australia-based diversified molecular diagnostics company. The Company is engaged in providing genomics-based tests on health, wellness and serious disease through its EasyDNA brand. It offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The Company has a proprietary risk stratification platform that integrates clinical and genetic risk to deliver outcomes to physicians and individuals. The Company's segments include EasyDNA, AffinityDNA, and GeneType/Corporate. The EasyDNA segment relates to EasyDNA branded test sales and expenses. The AffinityDNA segment relates to AffinityDNA branded test sales and expenses. GeneType/Corporate: relates to geneType branded test sales and expense, includes corporate charges.
Small Caps Research
No research on Genetic Technologies Ltd yet
We cover the ASX small-cap market one company at a time. Request coverage and we’ll prioritise GTG based on demand.
Share price
Market Statistics
Valuation
Trading Activity
Latest news
Market wrap: Australia bucks global trend as weak energy and miners deflate the ASX 200
Once again, Australia’s relative lack of technology stocks has seen the local market fail to keep pace with strong offshore leads. On Friday after all three major US equity benchmarks reset new highs, weakness in mining and energy stocks in Australia dragged the ASX 200 index down by 0.2% or 11.4 points, to 7770.6 points. […]
Genetic Technologies unveils GeneType test for unprecedented disease risk assessment
Molecular diagnostics company Genetic Technologies (ASX: GTG) has announced a major breakthrough in risk assessment tests for serious diseases. The new GeneType technology builds on the success of the company’s comprehensive hereditary breast and ovarian cancer test. The innovation will be a world first in identifying more than 200 high-penetrant genes to unlock the hereditary […]
Genetic Technologies to launch world-first comprehensive risk assessment test for breast and ovarian cancer
A ground-breaking comprehensive risk assessment test is set to be introduced by Genetic Technologies (ASX: GTG) to assesses the likelihood that a woman will develop breast and/or ovarian cancer, whether as a result of a hereditary genetic mutation or the much more prevalent familial or sporadic cancer. The test integrates Genetic Technologies’ patented and proprietary GeneType platform […]
ASX biotech stocks benefiting from the COVID-19 story
Normally investors shun speculative plays in times of market uncertainties, but that’s not been the case with ASX-listed life science stocks across the drug, diagnostics and device sectors. Naturally, the biotechs drawing a connection with fighting or detecting the virus – spurious or otherwise – have seen their valuations soar. Not that investor interest is […]
Looking for charts & signals? See the tab.
Unlock the full research library - free.
Create a free account to access every broker report, CEO interview, IPO alert, and daily market wrap. No credit card. No paywall.